Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Agilon Health ( (AGL) ) is now available.
Agilon health on February 25, 2026 reported fourth-quarter and full-year 2025 results showing platform membership declined to 625,000, driven by previously disclosed market exits, while revenue in the quarter rose 3% year on year to $1.57 billion but fell 2% to $5.93 billion for the full year. Profitability deteriorated sharply, with a 2025 gross loss of $160 million versus a prior-year gross profit, medical margin swinging to a $57 million loss, net loss widening to $391 million, and adjusted EBITDA loss nearly doubling to $296 million, even as management highlighted ongoing transformation efforts and a solid liquidity position with $285 million in cash and modest debt as it guides toward improved performance in 2026.
The fourth quarter of 2025 underscored the strain on agilon’s economics, as gross loss more than doubled to $91 million, medical margin turned negative $74 million, and adjusted EBITDA loss deepened to $142 million amid high medical cost trends in its Medicare Advantage book. Despite the worsening loss profile, the company reduced geography entry costs and maintained access to additional cash within its unconsolidated ACO entities, positioning itself to pursue its turnaround strategy in 2026 while absorbing the impact of strategic market exits and recalibrating growth around its remaining value-based care partnerships.
The most recent analyst rating on (AGL) stock is a Hold with a $0.73 price target. To see the full list of analyst forecasts on Agilon Health stock, see the AGL Stock Forecast page.
Spark’s Take on AGL Stock
According to Spark, TipRanks’ AI Analyst, AGL is a Neutral.
The score is held down primarily by weak financial performance (shrinking revenue, negative margins, and negative operating cash flow) and ongoing loss-heavy guidance from the latest earnings call. Technicals provide a modest near-term uplift, but valuation is hard to justify with negative earnings, and corporate-event risk is elevated due to the NYSE delisting notice.
To see Spark’s full report on AGL stock, click here.
More about Agilon Health
Agilon health, inc. is a physician enablement company that partners with primary care physicians to manage seniors’ care, primarily through Medicare Advantage and accountable care organization (ACO) models. The company operates a platform-based model focused on value-based care in U.S. communities, assuming medical risk while aiming to improve clinical outcomes and economics for its physician partners and payor relationships.
Average Trading Volume: 7,305,111
Technical Sentiment Signal: Sell
Current Market Cap: $163.3M
For detailed information about AGL stock, go to TipRanks’ Stock Analysis page.